Table 2. Analysis of subgroups in vaccine-associated cirAEs disproportionality.

Total Vaccine-associated cirAEs IC (IC0.25) based on age, years
Observed ROR (95% CI) IC (IC0.25) 0-11 12-17 18-44 45-64 ≥65
Total 8,562,584 8,354 0.60 (0.59-0.61) -0.70 (-0.73) -0.13 (-0.18) -1.42 (-1.60) -1.97 (-2.05) -1.56 (-1.66) -1.30 (-1.42)
Sex difference
Male 3,193,238 4,083 0.66 (0.64-0.69) -0.56 (-0.61) -0.01 (-0.08) -1.52 (-1.80) -2.01 (-2.15) -1.80 (-1.98) -1.09 (-1.27)
Female 5,277,250 4,070 0.55 (0.53-0.56) -0.83 (-0.88) -0.28 (-0.36) -1.31 (-1.54) -1.97 (-2.09) -1.40 (-1.53) -1.52 (-1.68)
Vaccine types
Anthrax vaccines 10,076 41 2.66 (1.96-3.62) 1.38 (0.86) 1.24 (-2.55) N/A 1.07 (0.52) -0.53 (-4.31) N/A
Cholera vaccines 2,709 1 0.24 (0.03-1.71) -1.63 (-5.42) N/A N/A N/A N/A N/A
DTaP-IPV-Hib vaccines 896,922 1,789 1.30 (1.25-1.37) 0.38 (0.30) -0.38 (-0.47) -0.80 (-1.29) -0.54 (-0.93) -0.11 (-0.62) -0.16 (-0.96)
Meningo coccal vaccines 159,108 240 0.98 (0.87-1.12) -0.02 (-0.24) -0.75 (-1.02) -1.32 (-1.86) -0.58 (-1.33) -1.45 (-5.24) 0.56 (-2.03)
Pneumo-coccal vaccines 306,355 619 1.32 (1.22-1.43) 0.40 (0.27) 0.00 (-0.16) N/A -0.90 (-1.80) -0.17 (-0.72) -0.21 (-0.55)
Tubercu-losis vaccines 36,964 9 0.16 (0.08-0.30) -2.59 (-3.73) N/A -0.59 (-2.35) -0.01 (-2.61) N/A N/A
Typhoid vaccines 17,799 50 1.84 (1.39-2.42) 0.86 (0.39) 1.16 (0.02) -0.71 (-4.50) 0.80 (0.21) -0.99 (-3.58) 1.03 (-1.04)
Encepha-litis vaccines 22,231 51 1.50 (1.14-1.97) 0.58 (0.11) 0.99 (0.38) -0.13 (-2.20) -0.36 (-1.44) -0.19 (-1.75) -0.32 (-2.92)
Influenza vaccines 388,584 611 1.03 (0.95-1.11) 0.04 (-0.10) 0.10 (-0.14) -0.96 (-1.69) -1.02 (-1.36) -0.46 (-0.78) 0.03 (-0.23)
Hepatitis A vaccines 65,942 210 2.08 (1.82-2.39) 1.05 (0.82) 0.77 (0.47) -0.28 (-1.15) 0.32 (-0.21) 0.61 (-0.21) -0.43 (-3.02)
Hepatitis B vaccines 113,846 389 2.24 (2.02-2.47) 1.15 (0.99) 0.91 (0.68) -0.02 (-0.67) 0.50 (0.16) 0.56 (-0.07) 1.14 (-0.28)
MMR vaccines 246,873 810 2.15 (2.01-2.30) 1.10 (0.98) 0.45 (0.33) 0.03 (-0.61) -0.66 (-1.31) -0.16 (-1.57) 0.40 (-3.38)
Rotavirus diarrhea vaccines 88,801 157 1.15 (0.99-1.35) 0.21 (-0.06) -0.47 (-0.75) N/A N/A N/A N/A
Zoster vaccines 233,054 407 1.14 (1.03-1.26) 0.19 (0.02) 0.63 (0.43) -1.20 (-2.33) -1.25 (-2.38) -1.33 (-1.97) -0.93 (-1.40)
Papillomavirus vaccines 147,925 150 0.66 (0.56-0.78) -0.59 (-0.86) -1.70 (-2.57) -1.34 (-1.71) -0.97 (-1.60) N/A N/A
COVID-19 mRNA vaccines 4,245,671 2,340 0.71 (0.68-0.74) -0.46 (-0.53) -1.40 (-1.86) -2.37 (-2.76) -2.28 (-2.41) -1.58 (-1.72) -1.65 (-1.82)
Ad5-vectored COVID-19 vaccines 1,330,416 248 0.24 (0.21-0.27) -2.02 (-2.23) N/A N/A -4.13 (-4.52) -2.82 (-3.16) -2.32 (-2.74)
Inactiva-ted whole-virus COVID-19 vaccines 180,528 24 0.17 (0.12-0.26) -2.49 (-3.17) -0.19 (-1.96) N/A -3.96 (-4.90) -4.92 (-7.52) -2.88 (-4.45)
Other viral vaccines* 20,311 122 3.94 (3.30-4.71) 1.95 (1.65) -0.03 (-1.59) N/A 2.54 (2.23) 0.06 (-1.70) -1.30 (-3.89)
Others** 48,469 86 1.16 (0.94-1.43) 0.21 (-0.15) -1.34 (-2.55) -0.68 (-2.44) -0.16 (-0.67) 0.57 (-0.18) -0.57 (-3.16)
Abbreviation: cirAEs, cutaneous immune-related adverse events; DTaP-IPV-Hib, diphtheria, tetanus toxoids, pertussis, polio, and Hemophilus influenza type b; IQR, interquartile range; MMR, measles, mumps, and rubella; TTO, time to onset; WHO, World Health Organization.
Bold style indicates when the value of IC0.25 is greater than 0.0 or the lower end of the ROR 95% CI is greater than 1.0. This means it is statistically significant.
Numbers in bold indicate a statistical significance.
Other viral vaccines: Dengue virus, Ebola, enterovirus 71, monkeypox, respiratory syncytial virus, and smallpox vaccines.
Others: Brucellosis, leptospirosis, plague, and yellow fever vaccines.